134523-02-7

Upstream product

• 125995-03-1 atorvastatin lactone 
• 125971-95-1 tert-butyl (4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxane-4-acetate 
• 1119697-15-2 atorvastatin lactone 
• 134395-00-9 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid t-butyl ester 
• 134523-00-5 atorvastatin 

Downstream Products

• 134523-03-8 lipitor 
• 125995-03-1 atorvastatin lactone 

Relevant academic research and scientific papers

Method for purifying atorvastatin calcium intermediate

The atorvastatin calcium intermediate is subjected to hydrolysis reaction to obtain the reaction liquid of atorvastatin calcium intermediate. The reaction liquid is extracted with a stripping solvent and is separated and separated to obtain an aqueous pha

Method for synthesizing atorvastatin calcium by using continuous flow tubular reactor

The invention relates to a method for synthesizing atorvastatin calcium by using a continuous flow tubular reactor, which comprises the following steps: (1) mixing atorvastatin tert-butyl ester with a solvent to obtain a material A; (2) adding sodium hydroxide into purified water to obtain a material B; (3) adding calcium acetate into purified water to obtain a material C; (4) respectively pumping the material A and the material B into a first tubular reactor for a chemical reaction, wherein the reaction temperature is 15-25 DEG C, and the reaction time is 20-50 s; then, continuously pumping the obtained reaction liquid and the material C into a second tubular reactor for a chemical reaction, wherein the reaction temperature ranges from 50 DEG C to 60 DEG C, the reaction time ranges from 30 s to 90 s, and obtaining a target product; wherein the specific synthesis route is as follows. By adopting the method disclosed by the invention, the required time of the whole reaction process is extremely short, the reaction condition is mild, the target product yield is high and reaches 96% or above, and the purity is high and reaches 99% or above.

Preparation method of crystal form I atorvastatin calcium

The invention discloses a preparation method of crystal form I atorvastatin calcium. The method includes the steps of: preparation of atorvastatin ester; preparation of an atorvastatin salt; preparation of atorvastatin calcium; refining an atorvastatin ca

SOLID STATES OF ATORVASTATIN POTASSIUM

Atorvastatin potassium crystalline Forms A, B, E, F, and G are provided. Also provided are methods of preparing atorvastatin potassium crystalline Forms A, B, E, F, and G. Atorvastatin potassium crystalline Forms A, B, E, F, and G may be used to prepare pharmaceutical compositions useful for the treatment of hypercholesterolemia or hyperlipidemia.

PRODRUG OF ATROVASTATIN BY CHOLESTEROL'S SYNTHESIS INHIBITORS

The present invention relates to atorvastatin prodrugs or pharmaceutically acceptable salts thereof. The compound of the present invention is hydrolyzed to atorvastatin in a body and allows atorvastatin to be maintained in a concentration effective in inhibiting the production of cholesterol for a long time. Further, the compound of the present invention can reduce side effects caused by an initial high concentration of atorvastatin in blood, thereby improving safety problems remarkably. Therefore, the compound of the present invention is effective in treating or preventing various diseases caused by excessive cholesterol such as hyperlipidemia, etc.

NOVEL POLYMORPHS OF THE POTASSIUM SALT OF ATORVASTATIN

Novel polymorphs Forms I, II and III of the potassium salt of Atorvastatin, (βR,δR)-2-(p-fluorophenyl)-( β,δ-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-l -heptanoic acid, are obtained directly by precipitation of the potassium salt of Atorv